Did you miss IGM Biosciences at Jefferies London Healthcare Conference this morning but still want to know what’s new at IGM, key takeaways from our experience at #ACR24, and the latest on imvotamab’s clinical development in autoimmunity?? We've got you covered!? You can find the full fireside chat with Dr. Lisa Decker, our Chief Business Officer, and Misbah Tahir, our Chief Financial Officer, here: https://lnkd.in/esBikAnp
IGM Biosciences, Inc.
生物技术研究
Mountain View，California 10,622 位关注者
Pioneering the development of engineered IgM antibodies
关于我们
About IGM Biosciences, Inc. IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites, compared to conventional IgG antibodies with only 2 binding sites. We have created unique IgM antibodies with high selectivity, affinity, and avidity that may redefine what is possible for therapeutic antibody medicines. We are committed to exploring how the unique structure and binding properties of the IGM antibody can improve outcomes for patients with these serious conditions. The Company also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology, immunology, and inflammation targets. For more information, please visit www.igmbio.com. Imvotamab in Autoimmune and Inflammatory Diseases Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. We believe that Imvotamab, with its 10 binding units for CD20, may successfully bind to CD20 expressing B cells with more power (avidity) compared to an IgG bispecific antibody with only one or two binding units for CD20. Our preclinical studies suggest that Imvotamab may offer the potential for deeper depletion of B cells, including those in low CD20 expressing cells, than currently approved antibody therapies. We are evaluating Imvotamab in Phase 1b clinical trials of Imvotamab in severe systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and idiopathic inflammatory myopathies (myositis).
- 网站
-
https://igmbio.com/platform/
IGM Biosciences, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Mountain View，California
- 类型
- 上市公司
- 创立
- 2010
- 领域
- Autoimmunity、Inflamation、Bispecific和Antibody
地点
IGM Biosciences, Inc.员工
动态
-
ICYMI, excellent conversation with IGM's CEO, Dr. Mary Beth Harler, about opportunities for B-cell depleting therapies, including imvotamab, in autoimmune diseases at yesterday's Stifel Healthcare Conference in New York. https://lnkd.in/eQKzN9u6
-
-
Interested in learning more about IGM’s ongoing work in Autoimmunity? Dr. Mary Beth Harler, CEO of IGM Biosciences, will participate in a fireside chat TODAY at 12:40 pm EST at the Stifel Healthcare Conference in New York. A live webcast will be available on the “Events and Presentations” page in the “Investors” section of our website.? Hope you can join!
-
There was a lot of interest in imvotamab’s potential to effectively deplete low-expressing CD20+ B cells in preclinical models of autoimmune disease during Sunday morning's SLE-Treatment Poster Session at #ACR24! If you missed the session but would like to discuss, please reach out to a member of our team!
-
-
We’re excited to see you at ACR Convergence 2024!?Please plan to stop by our poster presentation during the SLE – Treatment Poster II Session on Sunday, November 17th from 10:30am – 12:30pm. We look forward to discussing our preclinical data demonstrating imvotamab’s potential to deplete low target expressing cells more effectively than conventional effector function IgG antibodies through T cell-dependent cellular cytotoxicity (TDCC) and complement-dependent cytotoxicity (CDC). #ACR24
-
Looking for an interesting read on your way to Washington, DC for ACR Convergence 2024 this weekend??Check out "Cutting-edge approaches to B-cell depletion in autoimmune diseases," an exciting Review Article published in Frontiers in Immunology this October by researchers from Stanford University, the University of Colorado-Anschutz, and IGM Biosciences. Just in time for #ACR24, the article provides an excellent overview of the role of B cells in autoimmune diseases, as well as an introduction to different types of B-cell depletion therapies being investigated for the treatment of those diseases, including IGM’s CD20 x CD3 bispecific IgM antibody, imvotamab!
-
Sr. Director, Talent Acquisition | MSHRM | PHR | RACR | Career Strategist | Artist | Curator
IGM Biosciences is hiring a hands-on strategic MD/Ph.D. Sr. Medical Director to develop, lead, and drive the clinical development strategy for the company’s current and future pipeline of Autoimmunity medicines. Apply below: #autoimmunediseases; #rheumatologist; #IGMS; #medicaldirector
-
Sr. Director, Talent Acquisition | MSHRM | PHR | RACR | Career Strategist | Artist | Curator
IGM Biosciences is hiring a Sr. Global Regulatory Affairs Director with expertise in autoimmune diseases and recent experience with gene therapy products managed by CBER (FDA). Apply below. #globalregulatoryaffairs; #SLE; #IGMS; #rheumatology
-
Sr. Director, Talent Acquisition | MSHRM | PHR | RACR | Career Strategist | Artist | Curator
IGM Biosciences, Inc. is seeking a Sr. Director of Regulatory Affairs to serve as the global regulatory lead (GRL) on several immunology programs. This role involves developing global regulatory strategies and implementing them for our expanding pipeline of autoimmune programs. #IGMS #autoimmune #autoimmunediseases #immunology #rheumatology #regulatoryaffairs
-
Sr. Director, Talent Acquisition | MSHRM | PHR | RACR | Career Strategist | Artist | Curator
Join our team! We are seeking a cross-functional collaborative Director, Supply Planning and Project Management with skills in clinical supply management, long-range planning, and tech transfer. hashtag #IGMS #clinicalsupply #GMProjectmanagement #biotechtransfer